QRG Capital Management Inc. Has $5.23 Million Stock Holdings in Novo Nordisk A/S $NVO

QRG Capital Management Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 29.1% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,431 shares of the company’s stock after acquiring an additional 32,145 shares during the period. QRG Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $5,234,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. CIBC Bancorp USA Inc. bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth approximately $19,519,000. Romano Brothers AND Company grew its position in Novo Nordisk A/S by 704.0% in the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock valued at $1,742,000 after acquiring an additional 29,978 shares during the period. Capital Investment Counsel LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth $3,727,000. Marathon Capital Management raised its stake in Novo Nordisk A/S by 43.9% during the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock worth $4,208,000 after acquiring an additional 25,230 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its holdings in shares of Novo Nordisk A/S by 131.9% during the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock valued at $3,917,000 after acquiring an additional 43,793 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Several valuation-focused articles say Novo Nordisk may be undervalued, with DCF and market-multiple checks suggesting the stock could trade below intrinsic value. Analysts also point to Medicare GLP-1 coverage as a potential demand tailwind for Ozempic/Wegovy and the broader GLP-1 franchise. Novo Nordisk (NVO) Stock May Be 48% Undervalued On Medicare GLP 1 Coverage
• Positive Sentiment: Research highlighting the fast-growing global diabetes drug market reinforces Novo Nordisk’s long-term growth opportunity, with GLP-1 therapies still central to the company’s competitive position. Novo Nordisk (NVO) Is At The Center Of A Fast Growing Diabetes Drug Market
• Positive Sentiment: Independent valuation checks and a strong GF Score also suggest Novo Nordisk remains attractive despite recent volatility, supporting the case that the stock may have room to recover further. Novo Nordisk AS (NVO) Stock Up 3.4% and Still Undervalued — GF Score: 76/100

Novo Nordisk A/S Trading Down 0.1%

NVO opened at $50.39 on Monday. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $224.97 billion, a PE ratio of 11.83, a PEG ratio of 4.60 and a beta of 0.77. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $71.79. The firm has a 50-day moving average price of $44.70 and a two-hundred day moving average price of $45.82.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NVO shares. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Sanford C. Bernstein assumed coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price objective on the stock. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Five analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.